Research Article: Pharmacokinetic-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing arthroplasty: a retrospective real-world study on perioperative bleeding risk and economic outcomes
Abstract:
This study aimed to compare the perioperative bleeding risk and economic outcomes of pharmacokinetic (PK)-guided versus weight-guided coagulation factor replacement regimens during the perioperative period for patients with hemophilia undergoing joint arthroplasty.
We conducted a retrospective analysis of clinical data from patients with hemophilia who underwent knee or hip joint arthroplasty at our center between 2013 and 2025.
Thirty-three male patients with a median age of 39?years were included. Twenty-five patients (75.8%) had severe hemophilia. Seventeen patients (51.5%) underwent total joint arthroplasty, and 16 (48.5%) underwent partial joint arthroplasty. Perioperative coagulation factor replacement was weight-guided in 22 patients (66.7%) and PK-guided in 11 patients (33.3%). Postoperative SF-6Dv2 scores indicated a significant improvement in quality of life compared to preoperative baselines. The PK-guided group demonstrated a significantly lower median hospitalization cost (138,232 RMB vs. 200,122 RMB, p =?0.0073) and lower median coagulation factor consumption (701.6?IU/kg vs. 892.9?IU/kg, p =?0.0304) compared to the weight-guided group. Median intraoperative blood loss and perioperative hemoglobin decrease were comparable between groups.
For patients with hemophilia undergoing joint arthroplasty, a PK-guided coagulation factor infusion regimen significantly reduced factor consumption and overall medical costs, without a statistically significant increase in perioperative bleeding risk compared with the weight-guided approach. These exploratory findings support the clinical and economic advantages of PK-guided management in this surgical setting and warrant confirmation in larger, prospective studies.
Introduction:
Hemophilia is one of the most common genetic bleeding disorders. Patients with hemophilia are prone to recurrent hemarthroses as the disease progresses, leading to hemophilic arthropathy (HA) ( 1 , 2 ). This condition can ultimately result in joint deformity and functional loss, representing one of the primary severe complications that impair the quality of life for these patients ( 3 , 4 ). For patients with end-stage hemophilic arthropathy, arthroplasty is currently the only effective treatment in clinical…
Read more